Daré Bioscience (NASDAQ:DARE – Get Free Report) will release its earnings data after the market closes on Thursday, March 28th. Analysts expect Daré Bioscience to post earnings of ($0.12) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Daré Bioscience Stock Up 7.7 %
DARE stock opened at $0.52 on Tuesday. Daré Bioscience has a 52-week low of $0.27 and a 52-week high of $1.10. The company has a market capitalization of $50.76 million, a PE ratio of -1.10 and a beta of 1.21. The stock’s 50 day moving average is $0.41 and its two-hundred day moving average is $0.40.
Institutional Trading of Daré Bioscience
Several institutional investors and hedge funds have recently bought and sold shares of DARE. Renaissance Technologies LLC increased its stake in shares of Daré Bioscience by 26.3% in the second quarter. Renaissance Technologies LLC now owns 718,821 shares of the biotechnology company’s stock worth $654,000 after acquiring an additional 149,762 shares during the last quarter. Jane Street Group LLC lifted its position in Daré Bioscience by 240.0% in the first quarter. Jane Street Group LLC now owns 75,342 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 53,180 shares during the period. State Street Corp increased its holdings in Daré Bioscience by 9.6% in the 1st quarter. State Street Corp now owns 247,710 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 21,600 shares during the period. Virtu Financial LLC raised its stake in shares of Daré Bioscience by 13.5% in the 4th quarter. Virtu Financial LLC now owns 77,469 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 9,227 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Daré Bioscience by 283.4% during the 4th quarter. Morgan Stanley now owns 67,646 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 50,000 shares during the period. Institutional investors and hedge funds own 7.41% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on DARE
About Daré Bioscience
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
Featured Stories
- Five stocks we like better than Daré Bioscience
- 3 Healthcare Dividend Stocks to Buy
- 5 Top-Rated Dividend Stocks With Double-Digit Upside
- Business Services Stocks Investing
- Should You Buy Boeing Stock After CEO Resignation Announcement?
- 3 Best Fintech Stocks for a Portfolio Boost
- These Are The Most Upgraded Stocks From Q1
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.